References
- 1. World Health Organization. Cancer. Fact Sheet No 297, February 2015[displayed 17 November 2016]. Available at http://www.who.int/mediacentre/factsheets/fs297/en/
- 2. Gresner P, Gromadzinska J, Wasowicz W. Polymorphism of selected enzymes involved in detoxification and biotransformation in relation to lung cancer. Lung Cancer 2007;57:1-25. doi: 10.1016/j.lungcan.2007.02.002
- 3. Vineis P, Anttila S, Benhamou S, Spinola M, Hirvonen A, Kiyohara C, Garte SJ, Puntoni R, Rannug A, Strange RC, Taioli E. Evidence of gene-gene interactions in lung carcinogenesis in a large pooled analysis. Carcinogenesis 2007;28:1902-5. doi: 10.1093/carcin/bgm039
- 4. Hrstka R, Coates PJ, Vojtesek B. Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment. J Cell Mol Med 2009;13:440-53. doi: 10.1111/j.1582-4934.2008.00634.x
- 5. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999;19:1092-100. doi: 10.1128/MCB.19.2.1092
- 6. Dumont P, Leu JI, Della Pietra AC III, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357-65. doi: 10.1038/ng1093
- 7. Qiao Q, Hu W. The association between TP53 Arg72Pro polymorphism and lung cancer susceptibility: evidence from 30,038 subjects. Lung 2013;191:369-77. doi: 10.1007/ s00408-013-9461-9
- 8. Ye XH, Bu ZB, Feng J, Peng L, Liao XB, Zhu XL, Sun XL, Yu HG, Yan DF, Yan SX. Association between the TP53 polymorphisms and lung cancer risk: a meta-analysis. Mol Biol Rep 2014;41:373-85. doi: 10.1007/s11033-013-2871-1
- 9. Zhang H, Hao S, Zhao J, Zhou B, Ren Y, Yan Y, Zhao Y. Common genetic variants in 53BP1 associated with nonsmall-cell lung cancer risk in Han Chinese. Arch Med Res 2014;45:84-9. doi: 10.1016/j.arcmed.2013.10.011
- 10. Wang X, Hao LR, Yue K. The TP53 codon 72 Pro/Pro genotype may be associated with an increased lung cancer risk in North China: an updated meta-analysis. Int J Clin Exp Med 2015;8:3120-6. PMID: 26064201
- 11. Chowdhury MK, Moniruzzaman M, Emran AA, Mostafa MG, Kuddus RH, Uddin MA. TP53 codon 72 polymorphisms and lung cancer risk in the Bangladeshi population. Asian Pac J Cancer Prev 2015;16:3493-8. doi: 10.7314/ APJCP.2015.16.8.3493
- 12. Guengerich FP, Kim DH, Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 1991;4:168-79. doi: 10.1021/tx00020a008
- 13. Oyama T, Sugio K, Uramoto H, Iwata T, Onitsuka T, Isse T, Nozoe T, Kagawa N, Yasumoto K, Kawamoto T. Increased cytochrome P450 and aryl hydrocarbon receptor in bronchial epithelium of heavy smokers with non-small cell lung carcinoma carries a poor prognosis. Front Biosci 2007;12:4497-503. PMID: 17485391
- 14. Watanabe J, Hayashi S, Nakachi K, Imai K, Suda Y, Sekine T, Kawajiri K. PstI and RsaI RFLPs in complete linkage disequilibrium at the CYP2E gene. Nucleic Acids Res 1990;18:7194. PMID: 1979861
- 15. Hayashi S, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5’-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem 1991;110:559-65. PMID: 1778977
- 16. Liu G, Miller DP, Zhou W, Thurston SW, Fan R, Xu LL, Lynch TJ, Wain JC, Su L, Christiani DC. Differential association of the codon 72 p53 and GSTM1 polymorphisms on histological subtype of non-small cell lung carcinoma. Cancer Res 2001;61:8718-22. PMID: 11751390
- 17. Gaspar P, Moreira J, Kvitko K, Torres M, Moreira A, Weimer T. CYP1A1, CYP2E1, GSTM1, GSTT1, GSTP1, and TP53 polymorphisms: do they indicate susceptibility to chronic obstructive pulmonary disease and non-small-cell lung cancer? Genet Mol Biol 2004;27:133-8. doi: 10.1590/S1415-47572004000200001
- 18. Tan C, Xu HY, Zhang CY, Zhang H, Chen CM, Zhang WM, Sun XY, Jin YT. Effect of CYP1A1 MSPI polymorphism on the relationship between TP53 mutation and CDKN2A hypermethylation in non-small cell lung cancer. Arch Med Res 2011;42:669-76. doi: 10.1016/j.arcmed.2011.11.008
- 19. Ada AO, Kunak SC, Hancer F, Soydas E, Alpar S, Gulhan M, Iscan M. Association between GSTM1, GSTT1, and GSTP1 polymorphisms and lung cancer risk in a Turkish population. Mol Biol Rep 2012;39:5985-93. doi: 10.1007/ s11033-011-1411-0
- 20. World Health Organization. Histological typing of lung tumours. Tumori 1981;67:253-72. [No authors listed] PMID: 6274068
- 21. Talseth BA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, Scott RJ. Age of diagnosis of colorectal cancer in HNPCC patients is more complex than that predicted by R72P polymorphism in TP53. Int J Cancer 2006;118:2479-84. doi: 10.1002/ijc.21661
- 22. Choi JY, Abel J, Neuhaus T, Ko Y, Harth V, Hamajima N, Tajima K, Yoo KY, Park SK, Noh DY, Han W, Choe KJ, Ahn SH, Kim SU, Hirvonen A, Kang D. Role of alcohol and genetic polymorphisms of CYP2E1 and ALDH2 in breast cancer development. Pharmacogenetics 2003;13:67-72. DOI: 10.1097/01.fpc.0000054060.98065.fc
- 23. Liu G, Miller DP, Zhou W, Thurston SW, Fan R, Xu LL, Lynch TJ, Wain JC, Su L, Christiani DC. Differential association of the codon 72 p53 and GSTM1 polymorphisms on histological subtype of non-small cell lung carcinoma. Cancer Res 2001;61:8718-22. PONOVLJENA REF. 16.
- 24. Yang S, Guo H, Wei B, Zhu S, Cai Y, Jiang P, Tang J. Association of miR-502-binding site single nucleotide polymorphism in the 3’-untranslated region of SET8 and TP53 codon 72 polymorphism with non-small cell lung cancer in Chinese population. Acta Biochim Biophys Sin (Shanghai) 2014;46:149-54. doi: 10.1093/abbs/gmt138
- 25. Loginov VI, Atkarskaia MV, Burdennyĭ AM, Zavarykina TM, Kazubskaia TP, Nosikov VV, Braga ÉA, Zhizhina GP. Association of Arg72Pro of TP53 and T309g of MDM2 genes with non-small-cell lung cancer in Russians of Moscow region. Mol Biol 2014;48:52-7. doi: 10.1134/ S0026893314010099
- 26. Szymanowska A, Jassem E, Dziadziuszko R, Borg A, Limon J, Kobierska-Gulida G, Rzyman W, Jassem J. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism. Lung Cancer 2006;52:9-14. doi: 10.1016/j. lungcan.2005.12.007
- 27. Fernández-Rubio A, López-Cima MF, González-Arriaga P, García-Castro L, Pascual T, Marrón MG, Tardón A. The TP53 Arg72Pro polymorphism and lung cancer risk in a population of Northern Spain. Lung Cancer 2008;61:309-16. doi: 10.1016/j.lungcan.2008.01.017
- 28. Wang Y, Yang H, Li L, Wang H, Zhang C, Yin G, Zhu B. Association between CYP2E1 genetic polymorphisms and lung cancer risk: a meta-analysis. Eur J Cancer 2010;46:758-64. doi: 10.1016/j.ejca.2009.12.010
- 29. Zhan P, Wang J, Zhang Y, Qiu LX, Zhao SF, Qian Q, Wei SZ, Yu LK, Song Y. CYP2E1 Rsa I/Pst I polymorphism is associated with lung cancer risk among Asians. Lung Cancer 2010;69:19-25. doi: 10.1016/j.lungcan.2009.09.001
- 30. Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland LB, Canzian F, Haugen A. A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers. Carcinogenesis 2008;29:1164-9. doi: 10.1093/ carcin/bgn020
- 31. Li W, Yue W, Zhang L, Zhao X, Ma L, Yang X, Zhang C, Wang Y, Gu M. Polymorphisms in GSTM1, CYP1A1, CYP2E1, and CYP2D6 are associated with susceptibility and chemotherapy response in non-small-cell lung cancer patients. Lung 2012;190:91-8. doi: 10.1007/s00408-011-9338-8
- 32. Cao L, Lin J, He B, Wang H, Rao J, Liu Y, Zhang X. A regulatory variant in CYP2E1 affects the risk of lung squamous cell carcinoma. Tumor Biol 2014;35:455-62. doi: 10.1007/s13277-013-1063-x
- 33. Klinchid J, Chewaskulyoung B, Saeteng S, Lertprasertsuke N, Kasinrerk W, Cressey R. Effect of combined genetic polymorphisms on lung cancer risk in northern Thai women. Cancer Genet Cytogenet 2009;195:143-9. doi: 10.1016/j. cancergencyto.2009.08.011